Sanofi Tests First Combined RSV and hMPV Vaccine in Adults Over 60

Respiratory syncytial virus and human metapneumovirus together account for a substantial burden of severe respiratory disease in older adults, contributing to hospitalizations, pneumonia, and death particularly during winter months. Despite this, no vaccine has ever been approved to protect against both pathogens simultaneously. Sanofi Pasteur's Phase 1/2 trial represents a meaningful step toward filling that gap.

The study enrolled adults aged 60 years and older and tested three dose levels of a novel combination RSV/hMPV vaccine candidate delivered as a single intramuscular injection. The primary objectives were to characterize the safety profile across dose groups and to measure the immunogenicity — the strength and quality of the immune response — generated by each dose level.

A subset of enrolled participants received a booster vaccination 12 months after their initial shot, allowing researchers to assess whether immunity could be sustainably reinforced over time. This booster arm adds important real-world relevance, since annual or periodic revaccination may ultimately be required for sustained protection in an aging population.

The trial has been completed, though detailed efficacy and immunogenicity results have not yet been published in peer-reviewed literature based on available information. The three-dose design allows investigators to identify an optimal balance between immune response strength and tolerability before advancing to larger Phase 3 studies.

For clinicians and public health practitioners, a single injection covering both RSV and hMPV would represent a practical advance in respiratory vaccine scheduling for older patients. Caveats include the early-phase nature of the trial, the absence of published efficacy data, and the focus on immunogenicity rather than clinical protection endpoints. Full results, when released, will be critical for understanding whether this candidate warrants broader development.